ISSN: 1540-1405
Journal Home
Journal Guideline
Journal of the National Comprehensive Cancer Network : JNCCN Q1 Unclaimed
Journal of the National Comprehensive Cancer Network : JNCCN is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 150. It has an SJR impact factor of 4,102 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 4,102.
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy:
Type of publications:
Publication frecuency: -


- €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
4,102
SJR Impact factor150
H Index200
Total Docs (Last Year)611
Total Docs (3 years)7359
Total Refs6158
Total Cites (3 years)523
Citable Docs (3 years)10.66
Cites/Doc (2 years)36.8
Ref/DocOther journals with similar parameters
Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1
Compare this journals
Aims and Scope
Best articles by citations
VATS Versus Open Surgery for Lung Cancer Resection: Moving Beyond the Incision
View moreHSR20-085: Real-World Study of Factors Associated With Breast Conserving Surgery for Females Diagnosed With Early Stage Breast Cancer
View moreHSR20-087: Prevalence and Correlates of Psychological Distress in Patients Enrolling on Phase I Clinical Trials Using the NCCN Distress Thermometer and Problem List
View moreHSR20-088: Clinical Impact of Adherence to NCCN Biomarker Testing Guidelines on Survival for Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer
View moreHSR20-090: Current Utilization of Genomic Testing and Barriers to Optimal Patient Care: A Targeted Literature Review
View moreHSR20-091: Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia
View moreHSR20-095: Progression-Free Survival, Overall Survival, and Tumor Response for Patients Diagnosed With Small Cell Lung Cancer Who Received First-Line Systemic Therapy
View moreHSR20-099: Cost Comparison of PARP Inhibitors in Women With Ovarian Cancer (OC) in the US HealthCare Market
View moreHSR20-100: Results From a Pilot Study Examining the Impact of Distress Screening and Referral on Cancer Patient Cost and Health Care Utilization
View moreHSR20-101: Real-World Chemoradiotherapy Use Among Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Retrospective Observational Study
View moreHSR20-102: Quality Outcomes in Colon Cancer
View moreThe State of Cancer Care in America: Impact of State Policy on Access to High-Quality Cancer Care
View moreThe Process of NCCN Guidelines‚Ñ¢ Adaptation to the Middle East and North Africa Region
View moreHSR20-103: Years of Potential Life Lost Due to Cervical and Uterine Cancer Deaths in the United States, 2000-2016
View moreHSR20-104: Treatment Patterns and Time Trends for Intrahepatic Cholangiocarcinoma (iCCA) Patients: A Real-World Retrospective Claims Study
View moreHSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network
View moreHSR20-106: Quantifying Patient Preferences for Attributes Associated With First-Line Treatment of Metastatic Non-Small Cell Lung Cancer
View moreHSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments
View moreHSR20-110: The Promotion of Exercise Oncology as a Standard Part of Clinical Practice
View moreHSR20-111: Characteristics, Treatment Patterns, Healthcare Resource Use and Costs among Pediatric Patients Diagnosed with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Retrospective Database Analysis
View moreHSR20-114: Impact of Social Determinants of Health on Unplanned Acute Care Service Utilization for Patients With Hematologic Malignancies
View moreNCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018
View moreNCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
View moreFrequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma
View more
Comments